LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up
LifeMD (NASDAQ: LFMD) announced the lowest nationwide cash-pay pricing for Wegovy and Ozempic at $199 per month for new patients, just hours before its rescheduled Q3 2025 earnings release. Here’s what it means for patients, investors, and the GLP‑1 weight-loss market LifeMD Announces $199 Cash-Pay Pricing for Wegovy and Ozempic This morning, LifeMD, Inc. (NASDAQ: LFMD) unveiled what it calls the lowest cash‑pay pricing available nationwide for the GLP‑1 weight‑loss drugs Wegovy and Ozempic, in continued collaboration with Novo Nordisk. MarketScreener+3GlobeNewswire+3Quiver Quantitative+3 Under the new offer: The move builds on LifeMD’s shift away from compounded GLP‑1s toward direct partnerships with